In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival.
Florian Nolte, Anna Hecht, Mark Reinwald, Daniel Nowak, Verena Nowak, Benjamin Hanfstein, Andreas Faldum, Thomas Büchner, Karsten Spiekermann, Cristina Sauerland, Wolf-Karsten Hofmann, Eva Lengfelder
Department of Hematology and Oncology, University Hospital Mannheim, University of Heidelberg, Heidelberg, Germany. florian.nolte@medma.uni-heidelberg.de
Leukemia research 2013 AprWe evaluated the prognostic value of BAALC expression in 86 patients with acute promyelocytic leukemia (APL). At 10 years, the overall survival (OS) was 66% in all patients and 75% in patients who achieved a complete remission (CR). Patients in the BAALC(low) group showed an OS of 87% as compared to 60% in the BAALC(high) group (p=0.019). This difference was more pronounced in treatment responders (92% vs. 70%; p=0.035). In multivariate analyses low BAALC expression retained its prognostic relevance. In conclusion, BAALC expression analysis might be useful in further risk stratification in APL patients. Copyright © 2012 Elsevier Ltd. All rights reserved.
Citation
Florian Nolte, Anna Hecht, Mark Reinwald, Daniel Nowak, Verena Nowak, Benjamin Hanfstein, Andreas Faldum, Thomas Büchner, Karsten Spiekermann, Cristina Sauerland, Wolf-Karsten Hofmann, Eva Lengfelder. In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival. Leukemia research. 2013 Apr;37(4):378-82
Mesh Tags
Substances
PMID: 23287429
View Full Text
